Barclays analyst Luke Sergott raised the firm’s price target on Repligen (RGEN) to $160 from $150 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen’s Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning
- Repligen initiated with a Buy at HSBC
- Repligen upgraded to Outperform from In Line at Evercore ISI
- Repligen price target raised to $205 from $204 at RBC Capital
- Repligen Appoints Violetta Hughes as Chief Accounting Officer